[
Arlen, P. M., Bianco, F., Dahut, W. L. (2008). Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J. Urol., 179 (6), 2181–2185; discussion 2185–2186.10.1016/j.juro.2008.01.099
]Search in Google Scholar
[
Bartsch, G., Horninger, W., Klocker, H. (2001). Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 58 (3), 417–424.10.1016/S0090-4295(01)01264-X
]Search in Google Scholar
[
Billis, A., Guimaraes, M. S., Freitas, L. L. (2008). The impact of the 2005 International Society of Urological Pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biop-sies. J. Urol., 180 (2), 548–5452; discussion 552–553.10.1016/j.juro.2008.04.018
]Search in Google Scholar
[
Carter, H. B., Pearson, J. D., Metter, E. J. (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 267 (16), 2215–2220.10.1001/jama.1992.03480160073037
]Search in Google Scholar
[
Choo, R., Klotz, L., Deboer, G., Danjoux, C., Morton, G. (2004). Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. Brit. J. Urol. Int., 94 (3), 295–298.10.1111/j.1464-410X.2004.04926.x
]Search in Google Scholar
[
D’Amico, A. V., Hanks, G. E. (1993). Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer, 72 (9), 2638–2643.10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N
]Search in Google Scholar
[
D’Amico, A. V., Chen, M. H., Roehl, K. A., Catalona, W. J. (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New Engl. J. Med., 351 (2), 125–135.10.1056/NEJMoa032975
]Search in Google Scholar
[
Eggener, S. E., Yossepowitch, O., Roehl, K. A. (2008). Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology, 71 (6), 1016–1019.10.1016/j.urology.2007.12.008
]Search in Google Scholar
[
Epstein, J. I., Allsbrook, W. C. J., Amin, M. B. (2005). ISUP grading committee. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcino-ma. Amer. J. Surg. Pathol., 29 (9), 1228–1242.
]Search in Google Scholar
[
Folkmanis, K., Eglitis, J., Jakubovskis, M., Lietuvietis, V., Folkmane, I, Isajevs, S. CD63 and DNA mismatch repair protein expression in prostate cancer. Proc. Latvian Acad. Sci., Section B, 75 (3), 180–185.10.2478/prolas-2021-0027
]Search in Google Scholar
[
Heidenreich, A. (2008). Identification of high-risk prostate cancer: Role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur. Urol., 54 (5), 976–977; discussion 978–979.10.1016/j.eururo.2008.06.077
]Search in Google Scholar
[
Ilic, D., O’Connor, D., Green, S. (2007). Screening for prostate cancer: A Cochrane systematic review. Cancer Causes Control., 18 (3), 279–285.10.1007/s10552-006-0087-6
]Search in Google Scholar
[
Khatami, A., Aus, G., Damber, J. E., Lilja, H., Lodding, P., Hugosson, J. (2007). PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int. J. Cancer, 120 (1), 170–174.
]Search in Google Scholar
[
Loeb, S., Kettermann, A., Ferrucci, L., Landis, P., Metter, E. J., Carter, H. B. (2008). PSA doubling time versus PSA velocity to predict high-risk prostate cancer: Data from the Baltimore Longitudinal Study of Aging. Eur. Urol., 54 (5), 1073–1080.10.1016/j.eururo.2008.06.076
]Search in Google Scholar
[
Loeb, S., Metter, E. J., Kac, D. (2012). Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. Brit. J. Urol. Int., 109 (4), 508–513.10.1111/j.1464-410X.2011.10900.x
]Search in Google Scholar
[
Loeb, S., Roehl, K. A., Helfand, B. T. (2010). Can prostate specific antigen velocity decrease insignificant prostate cancer detection? J. Urol., 183 (1), 112–116.10.1016/j.juro.2009.08.156
]Search in Google Scholar
[
Lorente, J. A., Morote, J., Raventos, C. (1996). Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J. Urol., 155 (4), 1348–1351.10.1097/00005392-199604000-00060
]Search in Google Scholar
[
Lu-Yao, G., Albertsen, P. C., Stamford, J. L. (2002). Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Con-necticut. Brit. Med. J., 325 (7367), 740.10.1136/bmj.325.7367.740
]Search in Google Scholar
[
McLaren, D. B., McKenzie, M., Duncan, G., Pickles, T. (1998). Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer, 82 (2), 342–348.
]Search in Google Scholar
[
Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A.M., Lam, T. B., Mason, M. D., van der Kwast, T. H. et al. (2020). Oncology Guidelines, Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/ (accessed 14.07.2021).
]Search in Google Scholar
[
Moul, J. W., Wu, H., Sun, L. (2004). Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J. Urol., 171 (3), 1141–1147.10.1097/01.ju.0000113794.34810.d0
]Search in Google Scholar
[
O’Brien, M. F., Cronin, A. M., Fearn, P. A. (2009). Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pre-treatment PSA alone in patients treated with radical prostatectomy. J. Clin. Oncol., 27 (22), 3591–3597.10.1200/JCO.2008.19.9794
]Search in Google Scholar
[
Oudard, S., Banu, E., Scotte, F. (2007). Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann. Oncol., 18 (11), 1828–1833.10.1093/annonc/mdm332
]Search in Google Scholar
[
Post, P. N., Kil, P.J., Coebergh, J. W. (1999). Trends in survival of prostate cancer in southeastern Netherlands 1971-1989. Int. J. Cancer, 81 (4), 551–554.10.1002/(SICI)1097-0215(19990517)81:4<551::AID-IJC8>3.0.CO;2-5
]Search in Google Scholar
[
Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281 (17), 1591–1597.10.1001/jama.281.17.1591
]Search in Google Scholar
[
Pruthi, R. S., Johnstone, I., Tu, I. P., Stamey, T. A. (1997). Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology, 49 (5), 737–742.10.1016/S0090-4295(97)00231-8
]Search in Google Scholar
[
Raaijmakers, R., Wildhagen, M. F., Ito, K. (2004). Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology, 63 (2), 316–320.10.1016/j.urology.2003.09.028
]Search in Google Scholar
[
Ramirez, M. L., Nelson, E. C., Devere White, R. W. (2008). Current applications for prostate-specific antigen doubling time. Eur. Urol., 54 (2), 291–300.10.1016/j.eururo.2008.04.003
]Search in Google Scholar
[
Rana, A., Karamanis, K., Lucas, M. G. (1992). Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Brit. J. Urol., 69 (3), 277–281.10.1111/j.1464-410X.1992.tb15528.x
]Search in Google Scholar
[
Ross, P. L., Mahmud, S., Stephenson, A. J., Souhami, L., Tanguay, S., Aprikian, A. G. (2004). Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: value of short-term PSADT determinations. Urology, 64 (2), 323–328.10.1016/j.urology.2004.03.020
]Search in Google Scholar
[
Schmid, H. P., McNeal, J. E., Stamey, T. A. (1993). Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71 (6), 2031–2040.10.1159/000474708
]Search in Google Scholar
[
Schröder, F. H., Hugosson, J., Roobol, M. J. (2009). ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. New Engl. J. Med., 360 (13), 1320.
]Search in Google Scholar
[
Sengupta, S., Blute, M. L., Bagniewski, S. M. (2006). Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: Doubling time predicts survival. J. Urol., 175 (5),1684–1690.10.1016/S0022-5347(05)00978-X
]Search in Google Scholar
[
Spurgeon, S. E., Mongoue-Tchokote, S., Collins, L. (2007). Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology, 69 (5), 931–935.10.1016/j.urology.2007.01.075
]Search in Google Scholar
[
Stephenson, A. J., Aprikian, A. G., Souhami, L., Behlouli, H., Jacobson, A. I., Bégin, L. R., Tanguay, S. (2002). Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology, 59 (5), 652–656.10.1016/S0090-4295(02)01526-1
]Search in Google Scholar
[
Stewart, A. J., Scher, H. I., Chen, M. H. (2005). Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J. Clin. Oncol., 23 (27), 6556–6560.10.1200/JCO.2005.20.96616170163
]Search in Google Scholar
[
Thompson, I. M., Pauler, D. K., Goodman, P. J. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New Engl. J. Med., 350 (22), 2239–2246.10.1056/NEJMoa03191815163773
]Search in Google Scholar
[
Vickers, A. J., Savage, C., O’Brien, M. F. (2009). Systematic review of pre-treatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol., 27 (3), 398–403.10.1200/JCO.2008.18.1685264585419064972
]Search in Google Scholar
